{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:51:19Z","timestamp":1769824279906,"version":"3.49.0"},"reference-count":21,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,6]]},"DOI":"10.31744\/einstein_journal\/2024rc1111","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:38:44Z","timestamp":1731001124000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment of facial lipodystrophy induced by a biologic agent (IPD-1): a literature review"],"prefix":"10.31744","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3467-2222","authenticated-orcid":false,"given":"Henri","family":"Friedhofer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3134-0003","authenticated-orcid":false,"given":"Cristina Pires","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8489-4228","authenticated-orcid":false,"given":"Leandro Hirokazu","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0310-7084","authenticated-orcid":false,"given":"Daniel de Almeida Rocha","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-4478","authenticated-orcid":false,"given":"Rolf","family":"Gemperli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"issue":"8","key":"key20241107173839_B1","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma","volume":"104","author":"Falcao","year":"2019","unstructured":"1 Falcao CK, Cabral MC, Mota JM, Arbache ST, Costa-Riquetto AD, Muniz DQ, et al. Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma. J Clin Endocrinol Metab. 2019;104(8):3245-48.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20241107173839_B2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","unstructured":"2 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64. Review.","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"key20241107173839_B3","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","unstructured":"3 Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-68.","journal-title":"J Clin Oncol"},{"issue":"1","key":"key20241107173839_B4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","unstructured":"4 Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29(1):250-5.","journal-title":"Ann Oncol"},{"issue":"1","key":"key20241107173839_B5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/1078155219841116","article-title":"Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event","volume":"26","author":"Yilmaz","year":"2020","unstructured":"5 Yilmaz M. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event. J Oncol Pharm Pract. 2020;26(1):236-9.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"key20241107173839_B6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","unstructured":"6 Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-82.","journal-title":"JAMA Oncol"},{"issue":"8","key":"key20241107173839_B7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","unstructured":"7 Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471-80. Review.","journal-title":"Diabetes"},{"key":"key20241107173839_B8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document","volume":"89","author":"Riley","year":"2017","unstructured":"8 Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, et al. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017;89:218-35.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"key20241107173839_B9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/PRS.0000000000001590","article-title":"The current state of fat grafting: a review of harvesting, processing, and injection techniques","volume":"136","author":"Strong","year":"2015","unstructured":"9 Strong AL, Cederna PS, Rubin JP, Coleman SR, Levi B. The current state of fat grafting: a review of harvesting, processing, and injection techniques. Plast Reconstr Surg. 2015;136(4):897-912. Review.","journal-title":"Plast Reconstr Surg"},{"issue":"10","key":"key20241107173839_B10","first-page":"1513","article-title":"Facial lipodystrophy after immunotherapy with Nivolumab","volume":"19","author":"Drexler","year":"2021","unstructured":"10 Drexler K, Zenderowski V, Berneburg M, Haferkamp S. Facial lipodystrophy after immunotherapy with Nivolumab. J Dtsch Dermatol Ges. 2021;19(10):1513-5.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"key20241107173839_B11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bjd.18124","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","volume":"182","author":"Haddad","year":"2020","unstructured":"11 Haddad N, Vidal-Trecan T, Baroudjian B, Zagdanski AM, Arangalage D, Battistella M, Gautier JF, Lebbe C, Delyon J; PATIO group. Acquired generalized lipodystrophy under immune checkpoint inhibition. Br J Dermatol. 2020;182(2):477-80.","journal-title":"Br J Dermatol"},{"issue":"8","key":"key20241107173839_B12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cup.13273","article-title":"Scleroderma-like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks","year":"2018","unstructured":"12 Tjarks BJ, Kerkvliet AM, Jassim AD, Bleeker JS. Scleroderma-like skin changes induced by checkpoint inhibitor therapy. J Cutan Pathol. 2018;45(8):615-8.","journal-title":"J Cutan Pathol"},{"issue":"10","key":"key20241107173839_B13","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc18-2535","article-title":"Acquired generalized lipodystrophy: a new cause of Anti-PD-1 immune-related diabetes","volume":"42","author":"Jehl","year":"2019","unstructured":"13 Jehl A, Cugnet-Anceau C, Vigouroux C, Legeay AL, Dalle S, Harou O, et al. Acquired generalized lipodystrophy: a new cause of Anti-PD-1 immune-related diabetes. Diabetes Care. 2019;42(10):2008-10.","journal-title":"Diabetes Care"},{"issue":"1","key":"key20241107173839_B14","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.4158\/ACCR-2019-0234","article-title":"A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma","volume":"6","author":"Bedrose","year":"2020","unstructured":"14 Bedrose S, Turin CG, Lavis VR, Kim ST, Thosani SN. A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma. AACE Clin Case Rep. 2020;6(1):e40-e5.","journal-title":"AACE Clin Case Rep"},{"issue":"6","key":"key20241107173839_B15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CMR.0000000000000660","article-title":"Acquired lipodystrophy associated with immune checkpoint inhibitors","volume":"30","author":"Gnanendran","year":"2020","unstructured":"15 Gnanendran SS, Miller JA, Archer CA, Jain SV, Hwang SJ, Peters G, et al. Acquired lipodystrophy associated with immune checkpoint inhibitors. Melanoma Res. 2020;30(6):599-602.","journal-title":"Melanoma Res"},{"issue":"2","key":"key20241107173839_B16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/RLU.0000000000002862","article-title":"Nivolumab-Induced Subcutaneous Fat Necrosis: Another FDG-Avid Immune-Related Adverse Event","volume":"45","author":"Bhargava","year":"2020","unstructured":"16 Bhargava P, Flynt L, Marcal L. Nivolumab-Induced Subcutaneous Fat Necrosis: Another FDG-Avid Immune-Related Adverse Event. Clin Nucl Med. 2020;45(2):125-6.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"key20241107173839_B17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jamadermatol.2021.0058","article-title":"Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma","volume":"157","author":"Pach","year":"2021","unstructured":"17 Pach J, Olamiju B, Weiss S, Damsky W, Leventhal J. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma. JAMA Dermatol. 2021;157(4):468-9.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"key20241107173839_B18","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","unstructured":"18 Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350(12):1220-34. Review.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20241107173839_B19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy Syndromes","volume":"45","author":"Hussain","year":"2016","unstructured":"19 Hussain I, Garg A. Lipodystrophy Syndromes. Endocrinol Metab Clin North Am. 2016;45(4):783-97. Review.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"key20241107173839_B20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/hiv.12159","article-title":"The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection","volume":"15","author":"Guaraldi","year":"2014","unstructured":"20 Guaraldi G, Stentarelli C, Zona S, Santoro A, Beghetto B, Carli F, et al. The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection. HIV Med. 2014;15(10):587-94.","journal-title":"HIV Med"},{"issue":"9-10","key":"key20241107173839_B21","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1111\/jocn.14342","article-title":"\"We're stuck with what we've got\": The impact of lipodystrophy on body image","volume":"27","author":"Adams","year":"2018","unstructured":"21 Adams C, Stears A, Savage D, Deaton C. \"We're stuck with what we've got\": The impact of lipodystrophy on body image. J Clin Nurs. 2018;27(9-10):1958-68.","journal-title":"J Clin Nurs"}],"container-title":["Einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:38:51Z","timestamp":1731001131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/treatment-of-facial-lipodystrophy-induced-by-a-biologic-agent-ipd-1-a-literature-review\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":21,"alternative-id":["10.31744\/einstein_journal\/2024RC1111"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2024rc1111","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"eRC1111"}}